A small retrospective trial suggests that increasing level of serum CXCL8 can predict resistant to anti-PD-1 treatment in non-small-cell lung cancer (NSCLC) patients (Sanmamed et al., 2017). This evidence concerns the gene CXCL8 and non-small cell lung carcinoma.